Short Interest in DiaMedica Therapeutics Inc (NASDAQ:DMAC) Decreases By 68.4%

Share on StockTwits

DiaMedica Therapeutics Inc (NASDAQ:DMAC) was the recipient of a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 10,800 shares, a drop of 68.4% from the July 15th total of 34,200 shares. Based on an average trading volume of 109,700 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s shares are short sold.

In other DiaMedica Therapeutics news, Director Richard D. Pilnik purchased 19,000 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was purchased at an average cost of $2.80 per share, with a total value of $53,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have purchased a total of 30,840 shares of company stock valued at $83,240 over the last three months. 12.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Worth Venture Partners LLC increased its holdings in DiaMedica Therapeutics by 10.6% during the 2nd quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock worth $657,000 after purchasing an additional 12,651 shares during the period. BlackRock Inc. increased its holdings in DiaMedica Therapeutics by 159.7% during the 2nd quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock worth $134,000 after purchasing an additional 16,651 shares during the period. Vanguard Group Inc. purchased a new position in DiaMedica Therapeutics during the 2nd quarter worth $170,000. Eidelman Virant Capital purchased a new position in DiaMedica Therapeutics during the 2nd quarter worth $173,000. Finally, Granite Point Capital Management L.P. purchased a new position in DiaMedica Therapeutics during the 2nd quarter worth $1,141,000. Institutional investors own 8.73% of the company’s stock.

A number of equities research analysts recently issued reports on the company. Dougherty & Co assumed coverage on DiaMedica Therapeutics in a research note on Tuesday, April 30th. They set a “buy” rating and a $8.00 price target for the company. Zacks Investment Research lowered DiaMedica Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. Craig Hallum raised their price target on DiaMedica Therapeutics from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, ValuEngine raised DiaMedica Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $8.38.

DMAC traded down $0.01 during trading on Wednesday, hitting $2.50. 216 shares of the stock were exchanged, compared to its average volume of 55,483. The firm has a 50 day simple moving average of $3.37 and a 200 day simple moving average of $3.51. DiaMedica Therapeutics has a 1 year low of $2.15 and a 1 year high of $5.93. The company has a current ratio of 12.96, a quick ratio of 12.96 and a debt-to-equity ratio of 0.01.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. Analysts forecast that DiaMedica Therapeutics will post -0.91 earnings per share for the current year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

See Also: How does the Federal Reserve determine interest rates?

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Andersons  Sets New 12-Month Low at $18.02
Andersons Sets New 12-Month Low at $18.02
HCP  Reaches New 12-Month High at $36.84
HCP Reaches New 12-Month High at $36.84
Vitalhub  Shares Up 9.7%
Vitalhub Shares Up 9.7%
NextEra Energy  Price Target Raised to $252.00
NextEra Energy Price Target Raised to $252.00
Fortis  Given New $57.00 Price Target at JPMorgan Chase & Co.
Fortis Given New $57.00 Price Target at JPMorgan Chase & Co.
ConocoPhillips  Price Target Cut to $79.00 by Analysts at Morgan Stanley
ConocoPhillips Price Target Cut to $79.00 by Analysts at Morgan Stanley


© 2006-2019 Ticker Report